PT  - JOURNAL ARTICLE
AU  - Grumbach, Pascal
AU  - Kasper, Jan
AU  - Hipp, Joerg F.
AU  - Forsyth, Anna
AU  - Valk, Sofie L.
AU  - Muthukumaraswamy, Suresh
AU  - Eickhoff, Simon B.
AU  - Schilbach, Leonhard
AU  - Dukart, Juergen
TI  - Local activity alterations in autism spectrum disorder correlate with neurotransmitter properties and ketamine induced brain changes
AID  - 10.1101/2024.10.20.24315801
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.10.20.24315801
4099  - http://medrxiv.org/content/early/2024/10/21/2024.10.20.24315801.short
4100  - http://medrxiv.org/content/early/2024/10/21/2024.10.20.24315801.full
AB  - Autism spectrum disorder (ASD) is a neurodevelopmental condition associated with altered resting-state brain function. An increased excitation-inhibition (E/I) ratio is discussed as a potential pathomechanism but in-vivo evidence of disturbed neurotransmission underlying these functional alterations remains scarce. We compared rs-fMRI local activity (LCOR) between ASD (N=405, N=395) and neurotypical controls (N=473, N=474) in two independent cohorts (ABIDE1 and ABIDE2). We then tested how these LCOR alterations co-localize with specific neurotransmitter systems derived from nuclear imaging and compared them with E/I changes induced by GABAergic (midazolam) and glutamatergic medication (ketamine). Across both cohorts, ASD subjects consistently exhibited reduced LCOR, particularly in higher-order default mode network nodes, alongside increases in bilateral temporal regions, the cerebellum, and brainstem. These LCOR alterations negatively co-localized with dopaminergic (D1, D2, DAT), glutamatergic (NMDA, mGluR5), GABAergic (GABAa) and cholinergic neurotransmission (VAChT). The NMDA-antagonist ketamine, but not GABAa-potentiator midazolam, induced LCOR changes which co-localize with D1, NMDA and GABAa receptors, thereby resembling alterations observed in ASD. We find consistent local activity alterations in ASD to be spatially associated with several major neurotransmitter systems. NMDA-antagonist ketamine induced neurochemical changes similar to ASD-related alterations, supporting the notion that pharmacological modulation of the E/I balance in healthy individuals can induce ASD-like functional brain changes. These findings provide novel insights into neurophysiological mechanisms underlying ASD.One Sentence Summary: Local activity alterations in ASD co-localize with glutamatergic and GABAergic neurotransmission and were similar to ketamine-induced brain changes.Competing Interest StatementJ.F.H. is a current and J.D. is a former employee of F. Hoffmann La Roche Ltd. and received support in form of salaries.Funding StatementNo funding was received for this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Study was approved by a local Ethics Committee (Central Health and Disability Ethics Committee Ref: 15/CEN/254)). The trial registration can be found at https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=370230.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesKetamine and midazolam data are available upon reasonable request to the authors. The ABIDE datasets are available online at https://fcon_1000.projects.nitrc.org/indi/abide/